A Peek At What The LC-MS Assay And LC-MS Method Development Industry Will Look Like In 10 Years

HomeLifestyleHealthA Peek At What The LC-MS Assay And LC-MS Method Development Industry...

LC-MS assays are one of the vital bioanalytical techniques used in drug discovery and development studies. Moreover, tandem mass spectrometry with liquid chromatography (LC-MS/MS) is used in numerous diagnostic applications in laboratory medicine. Its importance is unquestioned in drug development and is often irreplaceable by traditional alternatives. The primary meaning of drug discovery and development is to identify potential drug candidates. Hence, robust systems such as LC-MS bioanalysis are crucial for the success of drug development projects.

Over time, the lcms testing have matured significantly. Today LC-MS applications are well understood, with the IVD industry shaping the future of LC-MS systems by bringing automated instruments to the market. However, LC-MS method development is still burdensome where LC-MS tests are developed locally. Though the future looks promising. Here we show what LC-MS assays and LC-MS method development industry will look like in the coming decade.

Promising future for LC-MS assays and LC-MS method development

Considering technologies available globally, mass spectrometry is a niche technology. Although the literature suggests that the extent of LC-MS systems has increased in the past decade, concrete numbers are not available. Besides, the overall use of LC-MS systems in biological laboratories will probably be less than one percent. However, the use of LC-MS in therapeutic drug monitoring (TDM) is much higher. For example, LC-MS/MS makes up to 70% of testing procedures used in immunosuppressive drugs TDM.

Soon LC-MS systems will be increasingly used in assessing biologics, with regulatory bodies readily accepting the data. Notably, as more complex biologics are developed, researchers will accumulate more knowledge of in vivo biotransformation of drug molecules. Moreover, advances in rapid digestion products and automated assay systems will further improve the efficiency of LC-MS assay. Also, technological advancements in micro-flow LC and software systems will make data processing more efficient and regulatory compliance.

Generally, strategies combining mass spectrometers for identifying analytes in complex biological samples will soon become more eminent. Besides, tandem mass spectrometry provides multiplexing capacities and can analyze multiple analytes in a single sample volume. Multiplexing systems will be critical mainly to assess inborn errors in newborn babies, where LC-MS systems can monitor many target analytes to understand the diagnostic purpose.

Today a broad range of IVD LC-MS/MS systems are available. These systems currently cover more than 150 target analytes. Such robust systems will surely improve the results of drug discovery process studies. Consequently, clinical trials will become safer and can adapt quickly to individual needs and foster personalized approaches. Moreover, LC-MS systems will replace immunoassays used in initial screening procedures will limited performance due to cross-reactivity with diagnostic antibodies.

LC-MS systems will promptly become the primary choice of the analytical method in endocrinology studies. This replacement will help researchers benefit from the enhanced specificity, sensitivity, and selectivity of LC-MS assays but will also replace several individual immunoassays required to assess multiple analytes in a single biological sample.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Must Read